Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies
S Paul, E Candelario-Jalil - Experimental neurology, 2021 - Elsevier
Stroke is the leading cause of disability and thesecond leading cause of death worldwide.
With the global population aged 65 and over growing faster than all other age groups, the …
With the global population aged 65 and over growing faster than all other age groups, the …
Poly (ADP-ribose) polymerase inhibition: past, present and future
The process of poly (ADP-ribosyl) ation and the major enzyme that catalyses this reaction,
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …
Oxidative stress and regulated cell death in Parkinson's disease
PA Dionísio, JD Amaral, CMP Rodrigues - Ageing research reviews, 2021 - Elsevier
Parkinson's disease (PD) is the second most common neurodegenerative disease
worldwide. Motor deficits usually associated with PD correlate with dopaminergic axonal …
worldwide. Motor deficits usually associated with PD correlate with dopaminergic axonal …
Role of mitochondrial ROS in the brain: from physiology to neurodegeneration
PR Angelova, AY Abramov - FEBS letters, 2018 - Wiley Online Library
Mitochondria are key cell organelles in that they are responsible for energy production and
control many processes from signalling to cell death. The function of the mitochondrial …
control many processes from signalling to cell death. The function of the mitochondrial …
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
Despite objective responses to poly (ADP-ribose) polymerase (PARP) inhibition and
improvements in progression-free survival (PFS) compared to standard chemotherapy in …
improvements in progression-free survival (PFS) compared to standard chemotherapy in …
Inhibitors of PARP: Number crunching and structure gazing
Selective inhibitors of PARP1 and PARP2 (PARP1/2) are used to treat cancer patients with
deficiencies in the repair of DNA via homologous recombination. Here we provide a …
deficiencies in the repair of DNA via homologous recombination. Here we provide a …
Poly (ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease
INTRODUCTION Parkinson's disease (PD) is the second most common neurodegenerative
disorder. Intracellular protein aggregates composed primarily of α-synuclein lead to …
disorder. Intracellular protein aggregates composed primarily of α-synuclein lead to …
Drug repositioning: Progress and challenges in drug discovery for various diseases
Y Hua, X Dai, Y Xu, G Xing, H Liu, T Lu, Y Chen… - European Journal of …, 2022 - Elsevier
Compared with traditional de novo drug discovery, drug repurposing has become an
attractive drug discovery strategy due to its low-cost and high efficiency. Through a …
attractive drug discovery strategy due to its low-cost and high efficiency. Through a …
The novel role of PPAR alpha in the brain: promising target in therapy of Alzheimer's disease and other neurodegenerative disorders
S Wójtowicz, AK Strosznajder, M Jeżyna… - Neurochemical …, 2020 - Springer
Peroxisome proliferator activated receptor alpha (PPAR-α) belongs to the family of ligand-
regulated nuclear receptors (PPARs). These receptors after heterodimerization with retinoid …
regulated nuclear receptors (PPARs). These receptors after heterodimerization with retinoid …
Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B1, B2, B3, and B5
M Hrubša, T Siatka, I Nejmanová, M Vopršalová… - Nutrients, 2022 - mdpi.com
This review summarizes the current knowledge on essential vitamins B1, B2, B3, and B5.
These B-complex vitamins must be taken from diet, with the exception of vitamin B3, that can …
These B-complex vitamins must be taken from diet, with the exception of vitamin B3, that can …